- Home
- DOYU vs AARD Comparison
DOYU vs AARD Comparison
Compare DOYU & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | AARD |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 165.8M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DOYU | AARD |
|---|---|---|
| Price | $4.31 | $6.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $15.29 |
| AVG Volume (30 Days) | 27.1K | ★ 116.7K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.18 | $3.35 |
| 52 Week High | $8.25 | $17.94 |
Technical Indicators
Market Signals| Indicator | DOYU | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 46.16 |
| Support Level | N/A | $5.12 |
| Resistance Level | $4.88 | $6.43 |
| Average True Range (ATR) | 0.17 | 0.87 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 19.39 | 33.71 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company aims to build an integrated game-centric ecosystem of livestreaming, video, voice, graphic content, and other interactive and community features. The company operates the platform both on mobile apps and PC portals, through which users can enjoy immersive and interactive games and entertainment livestreaming, access a wide array of video and graphic content, and participate in community events and discussions.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.